PASG - Passage Bio announces launch of proposed public offering of 7M shares

Genetic medicines company Passage Bio (PASG) announces that it has commenced an underwritten public offering of 7M shares of its common stock.Passage Bio intends to grant the underwriters a 30-day option to purchase up to an additional 1.05M shares at the public offering price, less underwriting discounts and commission.J.P. Morgan Securities, Goldman Sachs & Co. and Cowen and Company are acting as the joint bookrunning managers for the proposed offering. Wedbush Securities and Chardan are acting as co-managers.There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering, the company said.

For further details see:

Passage Bio announces launch of proposed public offering of 7M shares